Ac-225-DOTA-YS5
225Ac-DOTA-YS5 is a CD46-targeted PET radiopharmaceutical under evaluation for therapeutic [...]
Pb-212-ADVC001
212Pb-ADVC001 is an alpha-emitting PSMA targeting radiolabeled molecule developed in [...]
Lu-177-XT033
177Lu-XT033 is a PSMA targeting radiotherapeutic developed for the treatment [...]
Lu-177-AMTG
177Lu-AMTG is a radiolabeled bombesin analogue developed at the Technical [...]
Lu-177-HTK03170
177Lu-HTK03170 is the therapeutic 177Lu-labeled analogue of 68Ga-HTK03149, itself based [...]
Ac-225-FPI-2265
225Ac-FPI-2265 (225Ac-PSMA-I&T) is another alpha emitter analogue of the marketed [...]
Lu-177-PSMA-ALB-56
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]
Lu-177-Ludotadipep
177Lu-Ludotadipep (177Lu-FC705) is a 177Lu-labeled analogue of 177Lu-Vipivotide targeting PSMA. [...]
Tb-161-PSMA-I&T
161Tb-PSMA-I&T is a terbium analogue of 177Lu-Vipivotide tetraxetan and the [...]
Lu-177-rhPSMA-10.1
rhPSMA (radiohybrid PSMA) is a prostate specific membrane antigen labeled [...]